Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology CEO Vlad Vitoc reports updated ownership of the company’s common stock. He beneficially owns 3,846,352 shares of MAIA Biotechnology, Inc. common stock, representing 9.66% of the outstanding shares, based on 39,805,300 shares outstanding as of December 2, 2025. His holdings include shares owned directly by him and his spouse, as well as shares issuable upon the exercise of stock options and warrants held by him and certain family trusts. The filing states that he acquired these shares through equity award grants under the company’s incentive plans and through open-market purchases with personal funds.
The filing notes that Vitoc holds the shares for investment purposes and may buy more or sell some in the future, or use hedging strategies, subject to applicable law. During the 60 days prior to the filing, he purchased 94,300 shares of MAIA common stock in the open market at prices generally around $1 per share on several dates in November 2025.
MAIA Biotechnology, Inc. Chief Executive Officer and director Vlad Vitoc, a more than 10% owner of the company, reported an open-market purchase of common stock. On 11/25/2025, he bought 10,500 shares of MAIA common stock at a price of $0.9661 per share. Following this transaction, he directly owned 831,421 common shares and indirectly held 210,100 common shares through his spouse.
This filing is an amendment to a prior Form 4 originally filed on 11/28/2025. The amendment corrects the previously reported total share balance owned by Mr. Vitoc’s spouse and now reflects the correct indirect ownership amount, while also reiterating that he disclaims beneficial ownership of those spouse-held shares except to the extent of his economic interest.
MAIA Biotechnology’s chief executive officer, director and 10% owner Vlad Vitoc reported open‑market purchases of the company’s common stock and corrected prior share balances. On November 26, 2025, he bought 22,000 shares at a weighted average price of $1.0463 per share, and on November 28, 2025 he bought an additional 50,000 shares at a weighted average price of $1.1366 per share. Following these transactions, he directly owns 903,421 shares of MAIA common stock and has indirect beneficial ownership of 210,100 shares held by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. This Form 4 amendment corrects the previously reported total share balances for both his holdings and his spouse’s holdings.
MAIA Biotechnology (MAIA) insider Vlad Vitoc, the company’s Chief Executive Officer, director and a 10% owner, reported open-market purchases of MAIA common stock. On November 28, 2025, he bought 50,000 shares at a weighted average price of $1.1366 per share. On November 26, 2025, he bought an additional 22,000 shares at a weighted average price of $1.0463 per share.
After these transactions, Vitoc directly beneficially owns 881,421 shares of MAIA common stock and indirectly beneficially owns 210,000 shares through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
MAIA Biotechnology, Inc. director Cristian Luput reported open-market purchases of the company’s common stock. On 11/26/2025, he bought 20,000 shares at a price of $1.0808 per share. On 11/28/2025, he purchased an additional 18,145 shares at a weighted average price of $1.1149 per share, with individual trades ranging from $1.1147 to $1.1192. After these transactions, he beneficially owned 437,628 shares of MAIA common stock, held directly.
MAIA Biotechnology director reports open-market stock purchase
Stan V. Smith, a director of MAIA Biotechnology, Inc., reported buying 15,000 shares of MAIA common stock on 11/26/2025. The purchase was made in the open market at a weighted average price of $1.0388 per share, with individual trades executed between $1.03 and $1.051. Following this transaction, Mr. Smith beneficially owned 1,364,289 shares of MAIA common stock, held indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology director reports open-market share purchase. A company director filed a Form 4 disclosing the acquisition of 10,000 shares of MAIA Biotechnology common stock on 11/25/2025. The shares were purchased at a price of $0.9785 per share. Following this transaction, the director beneficially owns 399,483 shares of MAIA common stock, held directly.
MAIA Biotechnology, Inc. reported an insider share purchase by its Chief Executive Officer, director and 10% owner Vlad Vitoc. On 11/25/2025, he bought 10,500 shares of common stock at a weighted average price of $0.9661 per share, with individual trades ranging from $0.9606 to $0.9745. After this transaction, he directly holds 831,421 common shares. An additional 210,000 shares are held by his spouse, which he reports as indirectly beneficially owned but disclaims ownership beyond his economic interest.
MAIA Biotechnology director reports insider share purchases. Director Stan V. Smith filed a Form 4 showing two open-market purchases of MAIA common stock. On 11/24/2025, he bought 10,000 shares at a weighted average price of $0.99, with individual trades ranging from $0.9675 to $0.9899. On 11/25/2025, he bought another 15,000 shares at a weighted average price of $0.98, with trades between $0.9550 and $1.05. Following these transactions, he beneficially owns 1,349,289 shares indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology CEO share purchases were reported by Vlad Vitoc, who serves as Chief Executive Officer, Director and 10% owner of MAIA Biotechnology, Inc. (MAIA). On 11/21/2025, he bought 1,800 shares of common stock at a weighted average price of $0.92 per share, and on 11/24/2025 he bought an additional 10,000 shares at a price of $0.9891 per share.
Following these transactions, Vitoc directly beneficially owned 820,921 shares of MAIA common stock. The filing also notes 210,100 shares beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The weighted average disclosure indicates the 1,800-share purchase was executed in multiple trades within a narrow price range between $0.9128 and $0.9235.